New study aims to decode head and neck tumors using MRI and tissue tests

NCT ID NCT06085781

Recruiting now Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study looks at how head and neck tumors change during treatment using special MRI scans and tissue samples. Sixty adults with newly diagnosed head and neck cancer will take a pill called pimonidazole, which highlights low-oxygen areas in tumors, and undergo repeat imaging. The goal is to find markers that could guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pimonidazole (oral tablet) and functional MRI
What this could lead to: If successful, this could help doctors predict how head and neck tumors respond to treatment, leading to more personalized therapy plans.
What could go wrong: This is an early exploratory study with only 60 participants, so results may not apply to all patients. The biomarkers studied may not prove useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Locations

Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.